238 Main Street, 3rd Floor
About BlueRock Therapeutics
BlueRock Therapeutics is a leading engineered cell therapy company with a mission to develop regenerative medicines for intractable diseases. BlueRock Therapeutics’ cell+gene platform harnesses the power of cells to create new medicines for neurology, cardiology, and immunology indications.
BlueRock Therapeutics’ cell differentiation technology recapitulates the cell’s developmental biology to produce authentic cell therapies, which are further engineered for additional function. Utilizing these cell therapies to replace damaged or degenerated tissue brings the potential to restore or regenerate lost function.
BlueRock’s culture is defined by scientific innovation, the highest ethical standards and an urgency to bring transformative treatments to all who would benefit. The company strives to be a top employer of scientific talent, empowering every member of the team to make meaningful and lasting contributions to the burgeoning field of regenerative medicine.
Become a BlueRocker! We are expanding our BlueRock team at all locations. Contact us on our website to learn about rewarding career opportunities.
Our CEO, Seth Ettenberg, talking about the importance of Community at BlueRock.
54 articles about BlueRock Therapeutics
BlueRock Therapeutics, LP today announced its participation in the Cell & Gene Meeting on the Mesa, to be held Oct. 3-5 in La Jolla, Calif.
9/24/2018Here's a look at who's making moves in the biotech and pharma world this week.
Appointment strengthens the leadership team and accelerates the company's establishment of its novel Cell+Gene platform
It’s hard to believe 2018 is half over. There have been plenty of interesting and important stories in the biopharma space this year. Here’s a look at our top 10 stories so far, counting down from 10 to the number one story.
BlueRock Therapeutics Establishes R&D Site in New York City and Formalizes Collaboration with Memorial Sloan Kettering Cancer Center
Company Receives $1 Million Incentive Through Economic Development Initiative of New York State and Empire State Development
BlueRock Therapeutics, which has locations in Toronto, NYC and Cambridge, Mass., rocketed to existence in December 2016 with $225M in venture funding to focus on regenerative medicine, using iPSC therapies.
BioSpace is proud to present its NextGen "Class of 2018," a list of 20 up-and-coming life science companies in North America that started up no earlier than 2015.
BlueRock Therapeutics Announces Appointment of Derek Hei, Ph.D. as Senior VP, Manufacturing, Quality and Regulatory
Dr. Hei brings to BlueRock over twenty years of experience developing breakthrough cell and gene therapies from research through clinical trials.
BlueRock was founded in 2016 when Versant Ventures and Bayer invested $225 million in a Series A financing.
BlueRock Therapeutics And Universal Cells Enter Collaboration And License Agreement To Generate Gene-Edited iPS Cell Lines
BlueRock Therapeutics Expands Toronto Presence With R&D And Manufacturing Hub, Appoints Key R&D Leadership